BLVIS A Blue Vision A

UPDATE OF THE FINANCIAL CALENDAR FOR 2026

UPDATE OF THE FINANCIAL CALENDAR FOR 2026

UPDATE OF THE FINANCIAL CALENDAR FOR 2026

Hørsholm 18 March 2026

Company announcement no 2

Pharma Equity Group A/S updates its financial calendar for 2026. For technical reasons, the publication of the annual report is being postponed from 18 March 2026 to 25 March 2026. The date of the annual general meeting remains unchanged at 16 April 2026.

 



Pharma Equity Group

2026 Financial Calendar



 
​March 4Deadline for shareholder proposals - Annual General meeting​



 
​March 25 ​Annual Report 2025​



 
April 16Annual General Meeting​



 
August 14Interim Report – for the six-month period ended June 30, 2026​



 

​Contact person – Investor Relations

On the Company’s website further information and all published announcements can be found.

Inquiries regarding relations with investors and the stock market can be directed to: Christian Henrik Tange, CEO, Phone: E-mail: .

About Pharma Equity Group A/S

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.

Attachment



EN
18/03/2026

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

OPDATERING AF FINANSKALENDER FOR 2026

OPDATERING AF FINANSKALENDER FOR 2026 OPDATERING AF FINANSKALENDER FOR 2026 Hørsholm 18. marts 2026 Selskabsmeddelelse nr. 2 Pharma Equity Group A/S foretager en rettelse til finanskalenderen for 2026. Offentliggørelsen af årsregnskabet flyttes af tekniske årsager fra 18. marts 2026 til 25. marts 2026. Datoen for afholdelse af ordinær generalforsamling fastholdes til 16. april 2026.  Pharma Equity GroupFinanskalender for 2026 4. martsFrist for aktionærforslag - Ordinær generalforsamling 25. marts Årsrapport 2025 16. aprilOrdinær generalforsamling 14. augustDelårsrapport – for halvåret, d...

March 18, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

UPDATE OF THE FINANCIAL CALENDAR FOR 2026

UPDATE OF THE FINANCIAL CALENDAR FOR 2026 UPDATE OF THE FINANCIAL CALENDAR FOR 2026 Hørsholm 18 March 2026 Company announcement no 2 Pharma Equity Group A/S updates its financial calendar for 2026. For technical reasons, the publication of the annual report is being postponed from 18 March 2026 to 25 March 2026. The date of the annual general meeting remains unchanged at 16 April 2026.  Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 25 ​Annual Report 2025​ April 16Annual General Meeting​ August 14Interim Report – for...

March 18, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

KORRIGERENDE INFORMATION (SUPPLEMENTARY INFORMATION) TIL ÅRSRAPPORTEN...

KORRIGERENDE INFORMATION (SUPPLEMENTARY INFORMATION) TIL ÅRSRAPPORTEN FOR 2024 OG DELÅRSRAPPORTEN FOR 1. HALVÅR 2025 ORRIGERENDE INFORMATION (SUPPLEMENTARY INFORMATION) TIL ÅRSRAPPORTEN FOR 2024 OG DELÅRSRAPPORTEN FOR 1. HALVÅR 2025 Hørsholm 26. februar 2026 Selskabsmeddelelse nr. 1 Pharma Equity Group A/S ("Selskabet") offentliggør hermed konsekvenserne af en korrektion til Selskabets årsrapport for 2024 samt delårsrapport for 1. halvår 2025. INDHOLDSFORTEGNELSE Baggrund for den korrigerende informationLedelsespåtegningenDen uafhængige revisors erklæringKorrektion til Koncernregnska...

February 26, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPOR...

SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025 SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025 Hørsholm 26 February 2026 Company announcement #1 Pharma Equity Group A/S (the “Company”) hereby publishes the effects of a correction to the Company’s annual report for 2024 as well as the interim report for the first half of 2025. TABLE OF CONTENTS Background to the corrective informationManagement’s statementIndependent auditor’s reportCorrection to the consolid...

February 26, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Finans Kalender for 2026

Finans Kalender for 2026 3. februar 2026 Pressemeddelelse  Pharma Equity GroupFinans Kalender for 2026 4. martsFrist for aktionærforslag - Ordinær generalforsamling 18. marts Årsrapport 2025 16. aprilOrdinær generalforsamling 14. augustDelårsrapport – for halvåret, der sluttede 30. juni 2026  Kontaktperson – Investor Relations På selskabets hjemmeside kan yderligere information og alle offentliggjorte meddelelser findes. Henvendelser vedrørende Investor Relations og aktiemarkedet kan rettes til: Christian Henrik Tange, CEO, Telefon: E-mail: . Om Pharma Equity Group A/S Pharma Equity...

February 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch